Consumer Reports warns that there are important considerations, especially for older adults, before starting these treatments ...

Some workers are willing to trade vacation days or go back to the office in exchange for weight-loss drug coverage by their ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved ...

Impact on brown adipose tissue: Berberine may lower weight by increasing brown adipose tissue, a type of fat tissue that ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

STORY: Shares of Eli Lilly jumped Thursday morning after the company, known for its popular weight-loss drug Zepbound, forecast annual profit largely above Wall Street estimates.The outlook appeared ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

GLP-1s, which form the basis of Novo's Wegovy and rival Eli Lilly's Zepbound, work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors have now been eagerly ...

Analysts are particularly optimistic about the demand for tirzepatide, the active ingredient in Eli Lilly's flagship products Mounjaro and Zepbound ... Ozempic and Wegovy. However, Eli Lilly ...